Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 215-224

  Humphreys, Samantha ^a   Pellissier, James ^b   Jones, Alison ^c  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anti emetic therapy; CINV; Emesis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; METOCLOPRAMIDE; ONDANSETRON;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84881271498     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S44539     Document Type: Article

References (39)

1. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4): 219-227.
2. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol. 2003;21(22):4077-4080.
3. Ballatori E, Roila F, Ruggeri B, et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer. 2007;15(2):179-185.
4. Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer. 2004;12(10):708-715.
5. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5): 497-503.
6. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011; 19(1): 131-140.
7. Ihbe-Heffnger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization, and costs in German cancer centers. Ann Oncol. 2004;15(3): 526-536.
8. Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678-685.
9. Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park). 1998;12(3 Suppl 4):32-37.
10. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494.
11. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomized, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278-1285.
12. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet. 2012;379(9814):432-444.
13. National Institute for Health and Clinical Excellence (NICE). Early and locally advanced breast cancer: diagnosis and treatment. Full guideline (CG80); Feb 2009 [updated May 30, 2012]. Available from: http://www. nice.org.uk/CG80FullGuideline. Accessed Jun 2012.
14. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and defnition of antineoplastic agent emetogenicity an update. Support Care Cancer. 2005;13(2):80-84.
15. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21 Suppl 5:v232-v243.
16. University College Hospital NHS Foundation Trust. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy; 2010. Available from:http://www.medicinesresources.nhs.uk/upload/documents/Communities/London_CNDG/Antiemetic_guidelines_November_2010.pdf. Accessed Jun 2012.
17. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.
18. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112-4119.
19. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-3098.
20. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase 3 clinical trials. Eur J Cancer. 2004;40(3):403-410.
21. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-2830.
22. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104(7):1548-1555.
23. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4): 23-431.
24. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2010. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2010/index.php. Accessed Jun 2012.
25. Department of Health. NHS Reference Costs for 2009-2010. Appendix NSRC04: NHS trust and PCT combined reference cost schedules; 2011. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010. Accessed Jun 2012.
26. Monthly Index of Medical Specialities. [database on the Internet]. London: Haymarket Medical Media; 2011. Available from: http://www.mims.co.uk/go/mims_monthly. Accessed Jun 2012.
27. Joint Formulary Committee. British National Formulary. v. 61 edn. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London, UK; Mar 2011.
28. NHS Business Services Authority, NHS Prescription Services (compiled on behalf of the Department of Health). Drug Tariff. May 2011. Norwich: TSO; 2011.
29. Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 1996;4(6):435-439.
30. Borjeson S, Hursti TJ, Peterson C, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs. 1997;20(4):260-266.
31. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118-128.
32. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal; Jun 2008. Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed Jun 2012.
33. National Chemotherapy Advisory Group. Chemotherapy Services in England: Ensuring quality and safety. UK Department of Health; 2009. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354,http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_104501.pdf. Accessed Jun 2012.
34. Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986-1992.
35. Kris MG, Hesketh PJ, Somerfeld MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24(18):2932-2947.
36. Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and gran-isetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(3):1174-1178.
37. Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer. 2000;8(3):229-232.
38. Gridelli C, Ianniello G, Ambrosini G, et al. A multicenter, double-blind, randomized trial comparing ondansetron versus ondansetron plus dexa-methasone in the prophylaxis of cisplatin-induced delayed emesis. Int J Oncol. 1997;10(2):395-400.
39. Annemans L, Strens D, Lox E, Petit C, Malonne H. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer. 2008;16(8): 905-915.